Thompson K A, Blessing W W, Wesselingh S L
Infectious Diseases Unit, School of Medicine, Monash University, Victoria, Australia.
J Neurovirol. 2000 Feb;6(1):25-32. doi: 10.3109/13550280009006379.
Neurological damage in Herpes simplex type 1 encephalitis results from neuronal cell death secondary to viral invasion, and from inflammatory changes and cerebral oedema secondary to the immune response to the virus. Corticosteroids could have an important role in the management of Herpes simplex encephalitis because their anti-inflammatory action reduces cerebral oedema. However their use has been limited by concerns that their immunosuppressive actions could increase viral replication and spread. The present study examined this issue in a rat model in which injection of HSV-1 into the cervical vagus nerve produced a well-defined focal encephalitis, characterised by an orderly progression of the virus through central neural pathways connected with vagal afferent termination sites in the medulla oblongata. After injection of HSV-1, rats were treated twice a day, either with vehicle (saline, 400 microl i.p.), with acyclovir (30 mg/kg i.p.), with dexamethasone (5 mg/kg i.p.), or with both acyclovir and dexamethasone. Animals were sacrificed after 72 h, and viral load in different brain regions was quantified by computer-assisted measurement of the area occupied by immunohistochemical reaction product. Treatment with acyclovir reduced viral load to 17 +/- 5% of the saline value (P < 0.01). After dexamethasone treatment, the viral load (63 +/- 13% of the saline value) was also reduced (P < 0.05). Treatment with both acyclovir and dexamethasone reduced viral load to 26 +/- 8% of the saline value (P < 0.01 compared with saline, and P > 0.05 compared to acyclovir alone). Our results confirm the effectiveness of acyclovir in a new model of HSV-1 infection, and provide evidence that corticosteroids do not inhibit the antiviral action of acyclovir. In addition corticosteroids may decrease the extent of infection in their own right. The acute time course studied in our model parallels the time course of acute Herpes simplex encephalitis in humans. Our data suggests that corticosteroids are not detrimental when combined with acyclovir in the management of this condition.
1型单纯疱疹病毒性脑炎的神经损伤源于病毒入侵继发的神经元细胞死亡,以及对病毒免疫反应继发的炎症变化和脑水肿。皮质类固醇在单纯疱疹病毒性脑炎的治疗中可能发挥重要作用,因为其抗炎作用可减轻脑水肿。然而,由于担心其免疫抑制作用可能会增加病毒复制和传播,其应用受到了限制。本研究在大鼠模型中探讨了这个问题,在该模型中,将HSV-1注入颈迷走神经会产生明确的局灶性脑炎,其特征是病毒通过与延髓迷走神经传入终末部位相连的中枢神经通路有序进展。注射HSV-1后,大鼠每天接受两次治疗,分别给予溶剂(生理盐水,400微升腹腔注射)、阿昔洛韦(30毫克/千克腹腔注射)、地塞米松(5毫克/千克腹腔注射)或阿昔洛韦与地塞米松联合用药。72小时后处死动物,通过计算机辅助测量免疫组化反应产物所占面积来定量不同脑区的病毒载量。阿昔洛韦治疗可将病毒载量降至生理盐水组值的17±5%(P<0.01)。地塞米松治疗后,病毒载量(生理盐水组值的63±13%)也有所降低(P<0.05)。阿昔洛韦与地塞米松联合治疗可将病毒载量降至生理盐水组值的26±8%(与生理盐水组相比P<0.01,与单独使用阿昔洛韦相比P>0.05)。我们的结果证实了阿昔洛韦在HSV-1感染新模型中的有效性,并提供证据表明皮质类固醇不会抑制阿昔洛韦的抗病毒作用。此外,皮质类固醇本身可能会降低感染程度。我们模型中研究的急性病程与人类急性单纯疱疹病毒性脑炎的病程相似。我们的数据表明,在这种疾病的治疗中,皮质类固醇与阿昔洛韦联合使用并无害处。